#METABOLOMICS WORKBENCH RMbeach1053_20221121_093934 DATATRACK_ID:3589 STUDY_ID:ST002354 ANALYSIS_ID:AN003843 PROJECT_ID:PR001511
VERSION             	1
CREATED_ON             	November 22, 2022, 5:53 am
#PROJECT
PR:PROJECT_TITLE                 	Combination of TP-252 and Naproxen elicit tumor protective Eicosanoid changes.
PR:PROJECT_SUMMARY               	Comprehensive analysis of the lipidomic changes resulting from feeding with a
PR:PROJECT_SUMMARY               	over EPA analogue alone, and in combination with the NSAID naproxen.
PR:INSTITUTE                     	UConn Health
PR:DEPARTMENT                    	Center for Molecular Oncology
PR:LABORATORY                    	Rosenberg Laboratory
PR:LAST_NAME                     	Beach
PR:FIRST_NAME                    	Ryan
PR:ADDRESS                       	263 Farmington Avenue, Farmington, Connecticut, 06030, USA
PR:EMAIL                         	rbeach@uchc.edu
PR:PHONE                         	860-679-8703
PR:FUNDING_SOURCE                	NCI PREVENT funding
#STUDY
ST:STUDY_TITLE                   	Combination of TP-252 and Naproxen elicit tumor protective Eicosanoid changes.
ST:STUDY_SUMMARY                 	Colorectal cancer (CRC) is the second leading cause of cancer-related deaths in
ST:STUDY_SUMMARY                 	the United States. Patients with the genetic disorder Familial Adenomatous
ST:STUDY_SUMMARY                 	Polyposis (FAP) develop hundreds to thousands of polyps that unless removed by
ST:STUDY_SUMMARY                 	prophylactic colectomy will progress to CRC at an early age. Non-steroidal
ST:STUDY_SUMMARY                 	anti-inflammatory drugs (NSAIDs) and -3 marine polyunsaturated fatty acids
ST:STUDY_SUMMARY                 	(PUFA), such as eicosapentaenoic acid (EPA), have been evaluated for their
ST:STUDY_SUMMARY                 	chemopreventive potential in delaying the onset of CRC in high-risk patients. In
ST:STUDY_SUMMARY                 	this study, we determined whether the NSAID, naproxen, alone or in combination
ST:STUDY_SUMMARY                 	with a chemically-stable form of EPA (TP-252), affects tumor formation in the
ST:STUDY_SUMMARY                 	ApcPirc rat model. When compared to control diet, animals fed naproxen or HD
ST:STUDY_SUMMARY                 	TP-252 had 66%, and 82% fewer tumors respectively. However, when fed a
ST:STUDY_SUMMARY                 	combination of naproxen and HD TP-252, animals exhibited a 95% reduction in
ST:STUDY_SUMMARY                 	tumor formation and a 98% reduction in tumor volume, respectively. To elucidate
ST:STUDY_SUMMARY                 	potential mechanisms of tumor protection, a comprehensive, targeted lipidomic
ST:STUDY_SUMMARY                 	analysis was performed on colonic mucosa to determine changes in eicosanoid
ST:STUDY_SUMMARY                 	metabolism. Animals receiving TP-252 alone or in combination with naproxen had
ST:STUDY_SUMMARY                 	significantly reduced mucosal levels of pro-inflammatory -6 eicosanoids
ST:STUDY_SUMMARY                 	(PGE2, 5-HETE, and 14,15-DiHETrE), along with a simultaneous increase in
ST:STUDY_SUMMARY                 	anti-inflammatory EPA-derived -3 eicosanoids. Our colonic mucosal lipidomic
ST:STUDY_SUMMARY                 	analysis also uncovered several potential pharmacodynamic (PD) lipid biomarkers,
ST:STUDY_SUMMARY                 	including resolvin E2, 9-HEPE, 12-HEPE and 18-HEPE, that were increased in both
ST:STUDY_SUMMARY                 	the tissue and plasma of rats receiving TP-252 and were significantly correlated
ST:STUDY_SUMMARY                 	with tumor protection. Further studies with this drug combination should be
ST:STUDY_SUMMARY                 	focused on dose optimization and the role of EPA-derived lipid mediators in CRC
ST:STUDY_SUMMARY                 	initiation and progression.
ST:INSTITUTE                     	UConn Health
ST:LAST_NAME                     	Beach
ST:FIRST_NAME                    	Ryan
ST:ADDRESS                       	263 Farmington Avenue, Farmington CT 06030
ST:EMAIL                         	rbeach@uchc.edu
ST:PHONE                         	860-679-8703
#SUBJECT
SU:SUBJECT_TYPE                  	Mammal
SU:SUBJECT_SPECIES               	Rattus norvegicus
SU:TAXONOMY_ID                   	10116
SU:AGE_OR_AGE_RANGE              	26 weeks of age
SU:WEIGHT_OR_WEIGHT_RANGE        	320-460 grams
SU:GENDER                        	Male
SU:ANIMAL_ANIMAL_SUPPLIER        	RRRC (University of Missouri)
SU:ANIMAL_HOUSING                	Center for Comparative Medicine UConn
SU:ANIMAL_FEED                   	Modified AIN-93G diet from Research Diets
SU:ANIMAL_WATER                  	ab libitum
#SUBJECT_SAMPLE_FACTORS:         	SUBJECT(optional)[tab]SAMPLE[tab]FACTORS(NAME:VALUE pairs separated by |)[tab]Raw file names and additional sample data
SUBJECT_SAMPLE_FACTORS           	2440	TFA-T1	Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=TFA-T1.wiff
SUBJECT_SAMPLE_FACTORS           	2443	TFA-T2	Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=TFA-T2.wiff
SUBJECT_SAMPLE_FACTORS           	2538	TFA-T3	Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=TFA-T3.wiff
SUBJECT_SAMPLE_FACTORS           	2547	TFA-T4	Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=TFA-T4.wiff
SUBJECT_SAMPLE_FACTORS           	3181	TFA-T5	Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=TFA-T5.wiff
SUBJECT_SAMPLE_FACTORS           	3183	TFA-T6	Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=TFA-T6.wiff
SUBJECT_SAMPLE_FACTORS           	2444	TFA-T7	Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=TFA-T7.wiff
SUBJECT_SAMPLE_FACTORS           	2445	TFA-T8	Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=TFA-T8.wiff
SUBJECT_SAMPLE_FACTORS           	2446	TFA-T9	Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=TFA-T9.wiff
SUBJECT_SAMPLE_FACTORS           	2336	TFA-T10	Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=TFA-T10.wiff
SUBJECT_SAMPLE_FACTORS           	2850	TFA-T11	Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=TFA-T11.wiff
SUBJECT_SAMPLE_FACTORS           	2853	TFA-T12	Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=TFA-T12.wiff
SUBJECT_SAMPLE_FACTORS           	2853	TFA-T13	Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=TFA-T13.wiff
SUBJECT_SAMPLE_FACTORS           	3099	TFA-T14	Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=TFA-T14.wiff
SUBJECT_SAMPLE_FACTORS           	2448	TFA-T15	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=TFA-T15.wiff
SUBJECT_SAMPLE_FACTORS           	2449	TFA-T16	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=TFA-T16.wiff
SUBJECT_SAMPLE_FACTORS           	2450	TFA-T17	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=TFA-T17.wiff
SUBJECT_SAMPLE_FACTORS           	2901	TFA-T18	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=TFA-T18.wiff
SUBJECT_SAMPLE_FACTORS           	2903	TFA-T19	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=TFA-T19.wiff
SUBJECT_SAMPLE_FACTORS           	3020	TFA-T20	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=TFA-T20.wiff
SUBJECT_SAMPLE_FACTORS           	3021	TFA-T21	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=TFA-T21.wiff
SUBJECT_SAMPLE_FACTORS           	2451	TFA-T22	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=TFA-T22.wiff
SUBJECT_SAMPLE_FACTORS           	2453	TFA-T23	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=TFA-T23.wiff
SUBJECT_SAMPLE_FACTORS           	2454	TFA-T24	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=TFA-T24.wiff
SUBJECT_SAMPLE_FACTORS           	2884	TFA-T25	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=TFA-T25.wiff
SUBJECT_SAMPLE_FACTORS           	2885	TFA-T26	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=TFA-T26.wiff
SUBJECT_SAMPLE_FACTORS           	2271	TFA-T27	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=TFA-T27.wiff
SUBJECT_SAMPLE_FACTORS           	2282	TFA-T28	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=TFA-T28.wiff
SUBJECT_SAMPLE_FACTORS           	2344	TFA-T29	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=TFA-T29.wiff
SUBJECT_SAMPLE_FACTORS           	2458	TFA-T30	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=TFA-T30.wiff
SUBJECT_SAMPLE_FACTORS           	2460	TFA-T31	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=TFA-T31.wiff
SUBJECT_SAMPLE_FACTORS           	2463	TFA-T32	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=TFA-T32.wiff
SUBJECT_SAMPLE_FACTORS           	2878	TFA-T33	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=TFA-T33.wiff
SUBJECT_SAMPLE_FACTORS           	2879	TFA-T34	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=TFA-T34.wiff
SUBJECT_SAMPLE_FACTORS           	2883	TFA-T35	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=TFA-T35.wiff
SUBJECT_SAMPLE_FACTORS           	2386	TFA-T36	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=TFA-T36.wiff
SUBJECT_SAMPLE_FACTORS           	2743	TFA-T37	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=TFA-T37.wiff
SUBJECT_SAMPLE_FACTORS           	2747	TFA-T38	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=TFA-T38.wiff
SUBJECT_SAMPLE_FACTORS           	2899	TFA-T39	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=TFA-T39.wiff
SUBJECT_SAMPLE_FACTORS           	2900	TFA-T40	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=TFA-T40.wiff
SUBJECT_SAMPLE_FACTORS           	3029	TFA-T41	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=TFA-T41.wiff
SUBJECT_SAMPLE_FACTORS           	3030	TFA-T42	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=TFA-T42.wiff
SUBJECT_SAMPLE_FACTORS           	2738	TFA-T43	Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=TFA-T43.wiff
SUBJECT_SAMPLE_FACTORS           	2741	TFA-T44	Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=TFA-T44.wiff
SUBJECT_SAMPLE_FACTORS           	2847	TFA-T45	Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=TFA-T45.wiff
SUBJECT_SAMPLE_FACTORS           	2852	TFA-T46	Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=TFA-T46.wiff
SUBJECT_SAMPLE_FACTORS           	2854	TFA-T47	Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=TFA-T47.wiff
SUBJECT_SAMPLE_FACTORS           	3024	TFA-T48	Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=TFA-T48.wiff
SUBJECT_SAMPLE_FACTORS           	2385	TFA-T49	Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=TFA-T49.wiff
SUBJECT_SAMPLE_FACTORS           	3102	TFA-T50	Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=TFA-T50.wiff
SUBJECT_SAMPLE_FACTORS           	3104	TFA-T51	Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=TFA-T51.wiff
SUBJECT_SAMPLE_FACTORS           	2744	TFA-T52	Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=TFA-T52.wiff
SUBJECT_SAMPLE_FACTORS           	2745	TFA-T53	Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=TFA-T53.wiff
SUBJECT_SAMPLE_FACTORS           	2844	TFA-T54	Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=TFA-T54.wiff
SUBJECT_SAMPLE_FACTORS           	2845	TFA-T55	Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=TFA-T55.wiff
SUBJECT_SAMPLE_FACTORS           	2846	TFA-T56	Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=TFA-T56.wiff
SUBJECT_SAMPLE_FACTORS           	2440	EicoT1	Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=EicoT1.wiff
SUBJECT_SAMPLE_FACTORS           	2443	EicoT2	Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=EicoT2.wiff
SUBJECT_SAMPLE_FACTORS           	2538	EicoT3	Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=EicoT3.wiff
SUBJECT_SAMPLE_FACTORS           	2547	EicoT4	Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=EicoT4.wiff
SUBJECT_SAMPLE_FACTORS           	3181	EicoT5	Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=EicoT5.wiff
SUBJECT_SAMPLE_FACTORS           	3183	EicoT6	Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=EicoT6.wiff
SUBJECT_SAMPLE_FACTORS           	2444	EicoT7	Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=EicoT7.wiff
SUBJECT_SAMPLE_FACTORS           	2445	EicoT8	Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=EicoT8.wiff
SUBJECT_SAMPLE_FACTORS           	2446	EicoT9	Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=EicoT9.wiff
SUBJECT_SAMPLE_FACTORS           	2336	EicoT10	Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=EicoT10.wiff
SUBJECT_SAMPLE_FACTORS           	2850	EicoT11	Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=EicoT11.wiff
SUBJECT_SAMPLE_FACTORS           	2853	EicoT12	Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=EicoT12.wiff
SUBJECT_SAMPLE_FACTORS           	2853	EicoT13	Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=EicoT13.wiff
SUBJECT_SAMPLE_FACTORS           	3099	EicoT14	Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=EicoT14.wiff
SUBJECT_SAMPLE_FACTORS           	2448	EicoT15	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=EicoT15.wiff
SUBJECT_SAMPLE_FACTORS           	2449	EicoT16	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=EicoT16.wiff
SUBJECT_SAMPLE_FACTORS           	2450	EicoT17	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=EicoT17.wiff
SUBJECT_SAMPLE_FACTORS           	2901	EicoT18	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=EicoT18.wiff
SUBJECT_SAMPLE_FACTORS           	2903	EicoT19	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=EicoT19.wiff
SUBJECT_SAMPLE_FACTORS           	3020	EicoT20	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=EicoT20.wiff
SUBJECT_SAMPLE_FACTORS           	3021	EicoT21	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=EicoT21.wiff
SUBJECT_SAMPLE_FACTORS           	2451	EicoT22	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=EicoT22.wiff
SUBJECT_SAMPLE_FACTORS           	2453	EicoT23	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=EicoT23.wiff
SUBJECT_SAMPLE_FACTORS           	2454	EicoT24	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=EicoT24.wiff
SUBJECT_SAMPLE_FACTORS           	2884	EicoT25	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=EicoT25.wiff
SUBJECT_SAMPLE_FACTORS           	2885	EicoT26	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=EicoT26.wiff
SUBJECT_SAMPLE_FACTORS           	2271	EicoT27	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=EicoT27.wiff
SUBJECT_SAMPLE_FACTORS           	2282	EicoT28	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=EicoT28.wiff
SUBJECT_SAMPLE_FACTORS           	2344	EicoT29	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=EicoT29.wiff
SUBJECT_SAMPLE_FACTORS           	2458	EicoT30	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=EicoT30.wiff
SUBJECT_SAMPLE_FACTORS           	2460	EicoT31	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=EicoT31.wiff
SUBJECT_SAMPLE_FACTORS           	2463	EicoT32	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=EicoT32.wiff
SUBJECT_SAMPLE_FACTORS           	2878	EicoT33	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=EicoT33.wiff
SUBJECT_SAMPLE_FACTORS           	2879	EicoT34	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=EicoT34.wiff
SUBJECT_SAMPLE_FACTORS           	2883	EicoT35	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=EicoT35.wiff
SUBJECT_SAMPLE_FACTORS           	2386	EicoT36	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=EicoT36.wiff
SUBJECT_SAMPLE_FACTORS           	2743	EicoT37	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=EicoT37.wiff
SUBJECT_SAMPLE_FACTORS           	2747	EicoT38	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=EicoT38.wiff
SUBJECT_SAMPLE_FACTORS           	2899	EicoT39	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=EicoT39.wiff
SUBJECT_SAMPLE_FACTORS           	2900	EicoT40	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=EicoT40.wiff
SUBJECT_SAMPLE_FACTORS           	3029	EicoT41	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=EicoT41.wiff
SUBJECT_SAMPLE_FACTORS           	3030	EicoT42	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=EicoT42.wiff
SUBJECT_SAMPLE_FACTORS           	2738	EicoT43	Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=EicoT43.wiff
SUBJECT_SAMPLE_FACTORS           	2741	EicoT44	Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=EicoT44.wiff
SUBJECT_SAMPLE_FACTORS           	2847	EicoT45	Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=EicoT45.wiff
SUBJECT_SAMPLE_FACTORS           	2852	EicoT46	Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=EicoT46.wiff
SUBJECT_SAMPLE_FACTORS           	2854	EicoT47	Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=EicoT47.wiff
SUBJECT_SAMPLE_FACTORS           	3024	EicoT48	Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=EicoT48.wiff
SUBJECT_SAMPLE_FACTORS           	2385	EicoT49	Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=EicoT49.wiff
SUBJECT_SAMPLE_FACTORS           	3102	EicoT50	Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=EicoT50.wiff
SUBJECT_SAMPLE_FACTORS           	3104	EicoT51	Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=EicoT51.wiff
SUBJECT_SAMPLE_FACTORS           	2744	EicoT52	Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=EicoT52.wiff
SUBJECT_SAMPLE_FACTORS           	2745	EicoT53	Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=EicoT53.wiff
SUBJECT_SAMPLE_FACTORS           	2844	EicoT54	Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=EicoT54.wiff
SUBJECT_SAMPLE_FACTORS           	2845	EicoT55	Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=EicoT55.wiff
SUBJECT_SAMPLE_FACTORS           	2846	EicoT56	Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	RAW_FILE_NAME=EicoT56.wiff
SUBJECT_SAMPLE_FACTORS           	2538	TFA-P1	Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Fatty Acid | Tissue:Plasma	RAW_FILE_NAME=TFA-P1.wiff
SUBJECT_SAMPLE_FACTORS           	2547	TFA-P2	Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Fatty Acid | Tissue:Plasma	RAW_FILE_NAME=TFA-P2.wiff
SUBJECT_SAMPLE_FACTORS           	2442	TFA-P3	Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Fatty Acid | Tissue:Plasma	RAW_FILE_NAME=TFA-P3.wiff
SUBJECT_SAMPLE_FACTORS           	2440	TFA-P4	Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Fatty Acid | Tissue:Plasma	RAW_FILE_NAME=TFA-P4.wiff
SUBJECT_SAMPLE_FACTORS           	3183	TFA-P5	Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Fatty Acid | Tissue:Plasma	RAW_FILE_NAME=TFA-P5.wiff
SUBJECT_SAMPLE_FACTORS           	3181	TFA-P6	Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Fatty Acid | Tissue:Plasma	RAW_FILE_NAME=TFA-P6.wiff
SUBJECT_SAMPLE_FACTORS           	3190	TFA-P7	Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Fatty Acid | Tissue:Plasma	RAW_FILE_NAME=TFA-P7.wiff
SUBJECT_SAMPLE_FACTORS           	2165	TFA-P8	Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma	RAW_FILE_NAME=TFA-P8.wiff
SUBJECT_SAMPLE_FACTORS           	2167	TFA-P9	Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma	RAW_FILE_NAME=TFA-P9.wiff
SUBJECT_SAMPLE_FACTORS           	2168	TFA-P10	Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma	RAW_FILE_NAME=TFA-P10.wiff
SUBJECT_SAMPLE_FACTORS           	2333	TFA-P11	Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma	RAW_FILE_NAME=TFA-P11.wiff
SUBJECT_SAMPLE_FACTORS           	2444	TFA-P12	Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma	RAW_FILE_NAME=TFA-P12.wiff
SUBJECT_SAMPLE_FACTORS           	2445	TFA-P13	Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma	RAW_FILE_NAME=TFA-P13.wiff
SUBJECT_SAMPLE_FACTORS           	2853	TFA-P14	Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma	RAW_FILE_NAME=TFA-P14.wiff
SUBJECT_SAMPLE_FACTORS           	2264	TFA-P15	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Fatty Acid | Tissue:Plasma	RAW_FILE_NAME=TFA-P15.wiff
SUBJECT_SAMPLE_FACTORS           	2267	TFA-P16	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Fatty Acid | Tissue:Plasma	RAW_FILE_NAME=TFA-P16.wiff
SUBJECT_SAMPLE_FACTORS           	2265	TFA-P17	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Fatty Acid | Tissue:Plasma	RAW_FILE_NAME=TFA-P17.wiff
SUBJECT_SAMPLE_FACTORS           	2448	TFA-P18	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Fatty Acid | Tissue:Plasma	RAW_FILE_NAME=TFA-P18.wiff
SUBJECT_SAMPLE_FACTORS           	2449	TFA-P19	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Fatty Acid | Tissue:Plasma	RAW_FILE_NAME=TFA-P19.wiff
SUBJECT_SAMPLE_FACTORS           	2450	TFA-P20	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Fatty Acid | Tissue:Plasma	RAW_FILE_NAME=TFA-P20.wiff
SUBJECT_SAMPLE_FACTORS           	3020	TFA-P21	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Fatty Acid | Tissue:Plasma	RAW_FILE_NAME=TFA-P21.wiff
SUBJECT_SAMPLE_FACTORS           	2170	TFA-P22	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Fatty Acid | Tissue:Plasma	RAW_FILE_NAME=TFA-P22.wiff
SUBJECT_SAMPLE_FACTORS           	2169	TFA-P23	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Fatty Acid | Tissue:Plasma	RAW_FILE_NAME=TFA-P23.wiff
SUBJECT_SAMPLE_FACTORS           	2271	TFA-P24	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Fatty Acid | Tissue:Plasma	RAW_FILE_NAME=TFA-P24.wiff
SUBJECT_SAMPLE_FACTORS           	2451	TFA-P25	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Fatty Acid | Tissue:Plasma	RAW_FILE_NAME=TFA-P25.wiff
SUBJECT_SAMPLE_FACTORS           	2453	TFA-P26	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Fatty Acid | Tissue:Plasma	RAW_FILE_NAME=TFA-P26.wiff
SUBJECT_SAMPLE_FACTORS           	2284	TFA-P27	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Fatty Acid | Tissue:Plasma	RAW_FILE_NAME=TFA-P27.wiff
SUBJECT_SAMPLE_FACTORS           	2282	TFA-P28	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Fatty Acid | Tissue:Plasma	RAW_FILE_NAME=TFA-P28.wiff
SUBJECT_SAMPLE_FACTORS           	2344	TFA-P29	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma	RAW_FILE_NAME=TFA-P29.wiff
SUBJECT_SAMPLE_FACTORS           	2458	TFA-P30	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma	RAW_FILE_NAME=TFA-P30.wiff
SUBJECT_SAMPLE_FACTORS           	2352	TFA-P31	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma	RAW_FILE_NAME=TFA-P31.wiff
SUBJECT_SAMPLE_FACTORS           	2460	TFA-P32	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma	RAW_FILE_NAME=TFA-P32.wiff
SUBJECT_SAMPLE_FACTORS           	2879	TFA-P33	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma	RAW_FILE_NAME=TFA-P33.wiff
SUBJECT_SAMPLE_FACTORS           	2883	TFA-P34	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma	RAW_FILE_NAME=TFA-P34.wiff
SUBJECT_SAMPLE_FACTORS           	2463	TFA-P35	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma	RAW_FILE_NAME=TFA-P35.wiff
SUBJECT_SAMPLE_FACTORS           	2171	TFA-P36	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma	RAW_FILE_NAME=TFA-P36.wiff
SUBJECT_SAMPLE_FACTORS           	2174	TFA-P37	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma	RAW_FILE_NAME=TFA-P37.wiff
SUBJECT_SAMPLE_FACTORS           	2175	TFA-P38	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma	RAW_FILE_NAME=TFA-P38.wiff
SUBJECT_SAMPLE_FACTORS           	2386	TFA-P39	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma	RAW_FILE_NAME=TFA-P39.wiff
SUBJECT_SAMPLE_FACTORS           	2387	TFA-P40	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma	RAW_FILE_NAME=TFA-P40.wiff
SUBJECT_SAMPLE_FACTORS           	2900	TFA-P41	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma	RAW_FILE_NAME=TFA-P41.wiff
SUBJECT_SAMPLE_FACTORS           	2743	TFA-P42	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma	RAW_FILE_NAME=TFA-P42.wiff
SUBJECT_SAMPLE_FACTORS           	2385	TFA-P43	Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Fatty Acid | Tissue:Plasma	RAW_FILE_NAME=TFA-P43.wiff
SUBJECT_SAMPLE_FACTORS           	2394	TFA-P44	Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Fatty Acid | Tissue:Plasma	RAW_FILE_NAME=TFA-P44.wiff
SUBJECT_SAMPLE_FACTORS           	2398	TFA-P45	Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Fatty Acid | Tissue:Plasma	RAW_FILE_NAME=TFA-P45.wiff
SUBJECT_SAMPLE_FACTORS           	2738	TFA-P46	Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Fatty Acid | Tissue:Plasma	RAW_FILE_NAME=TFA-P46.wiff
SUBJECT_SAMPLE_FACTORS           	2741	TFA-P47	Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Fatty Acid | Tissue:Plasma	RAW_FILE_NAME=TFA-P47.wiff
SUBJECT_SAMPLE_FACTORS           	2847	TFA-P48	Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Fatty Acid | Tissue:Plasma	RAW_FILE_NAME=TFA-P48.wiff
SUBJECT_SAMPLE_FACTORS           	2852	TFA-P49	Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Fatty Acid | Tissue:Plasma	RAW_FILE_NAME=TFA-P49.wiff
SUBJECT_SAMPLE_FACTORS           	2177	TFA-P50	Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma	RAW_FILE_NAME=TFA-P50.wiff
SUBJECT_SAMPLE_FACTORS           	2180	TFA-P51	Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma	RAW_FILE_NAME=TFA-P51.wiff
SUBJECT_SAMPLE_FACTORS           	2384	TFA-P52	Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma	RAW_FILE_NAME=TFA-P52.wiff
SUBJECT_SAMPLE_FACTORS           	2389	TFA-P53	Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma	RAW_FILE_NAME=TFA-P53.wiff
SUBJECT_SAMPLE_FACTORS           	2391	TFA-P54	Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma	RAW_FILE_NAME=TFA-P54.wiff
SUBJECT_SAMPLE_FACTORS           	2744	TFA-P55	Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma	RAW_FILE_NAME=TFA-P55.wiff
SUBJECT_SAMPLE_FACTORS           	2745	TFA-P56	Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Fatty Acid | Tissue:Plasma	RAW_FILE_NAME=TFA-P56.wiff
SUBJECT_SAMPLE_FACTORS           	2538	EicoP1	Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Eicosanoid | Tissue:Plasma	RAW_FILE_NAME=EicoP1.wiff
SUBJECT_SAMPLE_FACTORS           	2547	EicoP2	Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Eicosanoid | Tissue:Plasma	RAW_FILE_NAME=EicoP2.wiff
SUBJECT_SAMPLE_FACTORS           	2442	EicoP3	Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Eicosanoid | Tissue:Plasma	RAW_FILE_NAME=EicoP3.wiff
SUBJECT_SAMPLE_FACTORS           	2440	EicoP4	Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Eicosanoid | Tissue:Plasma	RAW_FILE_NAME=EicoP4.wiff
SUBJECT_SAMPLE_FACTORS           	3183	EicoP5	Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Eicosanoid | Tissue:Plasma	RAW_FILE_NAME=EicoP5.wiff
SUBJECT_SAMPLE_FACTORS           	3181	EicoP6	Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Eicosanoid | Tissue:Plasma	RAW_FILE_NAME=EicoP6.wiff
SUBJECT_SAMPLE_FACTORS           	3190	EicoP7	Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Eicosanoid | Tissue:Plasma	RAW_FILE_NAME=EicoP7.wiff
SUBJECT_SAMPLE_FACTORS           	2165	EicoP8	Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma	RAW_FILE_NAME=EicoP8.wiff
SUBJECT_SAMPLE_FACTORS           	2167	EicoP9	Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma	RAW_FILE_NAME=EicoP9.wiff
SUBJECT_SAMPLE_FACTORS           	2168	EicoP10	Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma	RAW_FILE_NAME=EicoP10.wiff
SUBJECT_SAMPLE_FACTORS           	2333	EicoP11	Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma	RAW_FILE_NAME=EicoP11.wiff
SUBJECT_SAMPLE_FACTORS           	2444	EicoP12	Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma	RAW_FILE_NAME=EicoP12.wiff
SUBJECT_SAMPLE_FACTORS           	2445	EicoP13	Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma	RAW_FILE_NAME=EicoP13.wiff
SUBJECT_SAMPLE_FACTORS           	2853	EicoP14	Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma	RAW_FILE_NAME=EicoP14.wiff
SUBJECT_SAMPLE_FACTORS           	2264	EicoP15	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Eicosanoid | Tissue:Plasma	RAW_FILE_NAME=EicoP15.wiff
SUBJECT_SAMPLE_FACTORS           	2267	EicoP16	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Eicosanoid | Tissue:Plasma	RAW_FILE_NAME=EicoP16.wiff
SUBJECT_SAMPLE_FACTORS           	2265	EicoP17	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Eicosanoid | Tissue:Plasma	RAW_FILE_NAME=EicoP17.wiff
SUBJECT_SAMPLE_FACTORS           	2448	EicoP18	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Eicosanoid | Tissue:Plasma	RAW_FILE_NAME=EicoP18.wiff
SUBJECT_SAMPLE_FACTORS           	2449	EicoP19	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Eicosanoid | Tissue:Plasma	RAW_FILE_NAME=EicoP19.wiff
SUBJECT_SAMPLE_FACTORS           	2450	EicoP20	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Eicosanoid | Tissue:Plasma	RAW_FILE_NAME=EicoP20.wiff
SUBJECT_SAMPLE_FACTORS           	3020	EicoP21	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Eicosanoid | Tissue:Plasma	RAW_FILE_NAME=EicoP21.wiff
SUBJECT_SAMPLE_FACTORS           	2170	EicoP22	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Eicosanoid | Tissue:Plasma	RAW_FILE_NAME=EicoP22.wiff
SUBJECT_SAMPLE_FACTORS           	2169	EicoP23	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Eicosanoid | Tissue:Plasma	RAW_FILE_NAME=EicoP23.wiff
SUBJECT_SAMPLE_FACTORS           	2271	EicoP24	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Eicosanoid | Tissue:Plasma	RAW_FILE_NAME=EicoP24.wiff
SUBJECT_SAMPLE_FACTORS           	2451	EicoP25	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Eicosanoid | Tissue:Plasma	RAW_FILE_NAME=EicoP25.wiff
SUBJECT_SAMPLE_FACTORS           	2453	EicoP26	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Eicosanoid | Tissue:Plasma	RAW_FILE_NAME=EicoP26.wiff
SUBJECT_SAMPLE_FACTORS           	2284	EicoP27	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Eicosanoid | Tissue:Plasma	RAW_FILE_NAME=EicoP27.wiff
SUBJECT_SAMPLE_FACTORS           	2282	EicoP28	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Eicosanoid | Tissue:Plasma	RAW_FILE_NAME=EicoP28.wiff
SUBJECT_SAMPLE_FACTORS           	2344	EicoP29	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma	RAW_FILE_NAME=EicoP29.wiff
SUBJECT_SAMPLE_FACTORS           	2458	EicoP30	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma	RAW_FILE_NAME=EicoP30.wiff
SUBJECT_SAMPLE_FACTORS           	2352	EicoP31	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma	RAW_FILE_NAME=EicoP31.wiff
SUBJECT_SAMPLE_FACTORS           	2460	EicoP32	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma	RAW_FILE_NAME=EicoP32.wiff
SUBJECT_SAMPLE_FACTORS           	2879	EicoP33	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma	RAW_FILE_NAME=EicoP33.wiff
SUBJECT_SAMPLE_FACTORS           	2883	EicoP34	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma	RAW_FILE_NAME=EicoP34.wiff
SUBJECT_SAMPLE_FACTORS           	2463	EicoP35	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma	RAW_FILE_NAME=EicoP35.wiff
SUBJECT_SAMPLE_FACTORS           	2171	EicoP36	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma	RAW_FILE_NAME=EicoP36.wiff
SUBJECT_SAMPLE_FACTORS           	2174	EicoP37	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma	RAW_FILE_NAME=EicoP37.wiff
SUBJECT_SAMPLE_FACTORS           	2175	EicoP38	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma	RAW_FILE_NAME=EicoP38.wiff
SUBJECT_SAMPLE_FACTORS           	2386	EicoP39	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma	RAW_FILE_NAME=EicoP39.wiff
SUBJECT_SAMPLE_FACTORS           	2387	EicoP40	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma	RAW_FILE_NAME=EicoP40.wiff
SUBJECT_SAMPLE_FACTORS           	2900	EicoP41	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma	RAW_FILE_NAME=EicoP41.wiff
SUBJECT_SAMPLE_FACTORS           	2743	EicoP42	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma	RAW_FILE_NAME=EicoP42.wiff
SUBJECT_SAMPLE_FACTORS           	2385	EicoP43	Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Eicosanoid | Tissue:Plasma	RAW_FILE_NAME=EicoP43.wiff
SUBJECT_SAMPLE_FACTORS           	2394	EicoP44	Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Eicosanoid | Tissue:Plasma	RAW_FILE_NAME=EicoP44.wiff
SUBJECT_SAMPLE_FACTORS           	2398	EicoP45	Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Eicosanoid | Tissue:Plasma	RAW_FILE_NAME=EicoP45.wiff
SUBJECT_SAMPLE_FACTORS           	2738	EicoP46	Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Eicosanoid | Tissue:Plasma	RAW_FILE_NAME=EicoP46.wiff
SUBJECT_SAMPLE_FACTORS           	2741	EicoP47	Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Eicosanoid | Tissue:Plasma	RAW_FILE_NAME=EicoP47.wiff
SUBJECT_SAMPLE_FACTORS           	2847	EicoP48	Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Eicosanoid | Tissue:Plasma	RAW_FILE_NAME=EicoP48.wiff
SUBJECT_SAMPLE_FACTORS           	2852	EicoP49	Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Eicosanoid | Tissue:Plasma	RAW_FILE_NAME=EicoP49.wiff
SUBJECT_SAMPLE_FACTORS           	2177	EicoP50	Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma	RAW_FILE_NAME=EicoP50.wiff
SUBJECT_SAMPLE_FACTORS           	2180	EicoP51	Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma	RAW_FILE_NAME=EicoP51.wiff
SUBJECT_SAMPLE_FACTORS           	2384	EicoP52	Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma	RAW_FILE_NAME=EicoP52.wiff
SUBJECT_SAMPLE_FACTORS           	2389	EicoP53	Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma	RAW_FILE_NAME=EicoP53.wiff
SUBJECT_SAMPLE_FACTORS           	2391	EicoP54	Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma	RAW_FILE_NAME=EicoP54.wiff
SUBJECT_SAMPLE_FACTORS           	2744	EicoP55	Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma	RAW_FILE_NAME=EicoP55.wiff
SUBJECT_SAMPLE_FACTORS           	2745	EicoP56	Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Plasma	RAW_FILE_NAME=EicoP56.wiff
#COLLECTION
CO:COLLECTION_SUMMARY            	Animals were sacrificed by CO2 narcosis, and large intestines were excised,
CO:COLLECTION_SUMMARY            	washed with ice-cold PBS, and laid flat on filter paper. Tumor-adjacent
CO:COLLECTION_SUMMARY            	full-thickness colon segments were flash-frozen in liquid Nitrogen and stored at
CO:COLLECTION_SUMMARY            	-80C until analysis. Blood was collected via cardiac puncture and put in lithium
CO:COLLECTION_SUMMARY            	heparin tubes on ice. Samples were centrifuged at 2,000 g for 20 minutes, and
CO:COLLECTION_SUMMARY            	supernatant (plasma) was collected and stored at -80C until analysis.
CO:SAMPLE_TYPE                   	Blood (Plasma) and Large Intestine
#TREATMENT
TR:TREATMENT_SUMMARY             	Rats were fed two doses of TP-252 equivalent to consuming 1.3 and 2.6 g/kg/day
TR:TREATMENT_SUMMARY             	for LD TP-252 and HD TP-252, respectively. Alternatively, rats were also fed a
TR:TREATMENT_SUMMARY             	diet containing 2% EPA-FFA in their diet (equivalent to 1.14 g/kg/day of EPA).
TR:TREATMENT_SUMMARY             	In groups receiving naproxen, the dose of naproxen was 11.4 mg/kg/day, or
TR:TREATMENT_SUMMARY             	roughly 4 mg/rat/day. These treatment groups were carried out for the 20 weeks,
TR:TREATMENT_SUMMARY             	and then animals were sacrificed and tissue collected and analyzed.
#SAMPLEPREP
SP:SAMPLEPREP_SUMMARY            	Samples (0.85 ml) were spiked with 5 ng each (in 150 μl methanol) of
SP:SAMPLEPREP_SUMMARY            	15(S)-HETE-d8,14(15)-EpETrE-d11, Resolvin D2-d5, Leukotriene B4-d4, and
SP:SAMPLEPREP_SUMMARY            	Prostaglandin E1-d4 as internal standards for recovery and quantitation and
SP:SAMPLEPREP_SUMMARY            	mixed thoroughly. The samples were then extracted for PUFA metabolites using C18
SP:SAMPLEPREP_SUMMARY            	extraction columns as described earlier [1-4]. Briefly, the internal standard
SP:SAMPLEPREP_SUMMARY            	spiked samples were applied to conditioned C18 cartridges, washed with 15%
SP:SAMPLEPREP_SUMMARY            	methanol in water followed by hexane and dried under vacuum. The cartridges were
SP:SAMPLEPREP_SUMMARY            	eluted with 0.5 ml methanol. The eluate was dried under a gentle stream of
SP:SAMPLEPREP_SUMMARY            	nitrogen. The residue was redissolved in 50 μl methanol-25 mM aqueous ammonium
SP:SAMPLEPREP_SUMMARY            	acetate (1:1) and subjected to LC-MS analysis.
SP:SAMPLEPREP_PROTOCOL_FILENAME  	Methods of Eicosanoid Detection.pdf
#CHROMATOGRAPHY
CH:CHROMATOGRAPHY_SUMMARY        	HPLC was performed on a Prominence XR system (Shimadzu) using Luna C18 (3μ,
CH:CHROMATOGRAPHY_SUMMARY        	2.1x150 mm) column. The mobile phase consisted of a gradient between A:
CH:CHROMATOGRAPHY_SUMMARY        	methanol-water-acetonitrile (10:85:5 v/v) and B: methanol-water-acetonitrile
CH:CHROMATOGRAPHY_SUMMARY        	(90:5:5 v/v), both containing 0.1% ammonium acetate. The gradient program with
CH:CHROMATOGRAPHY_SUMMARY        	respect to the composition of B was as follows: 0-1 min, 50%; 1-8 min, 50-80%;
CH:CHROMATOGRAPHY_SUMMARY        	8-15 min, 80-95%; and 15-17 min, 95%. The flow rate was 0.2 ml/min. The HPLC
CH:CHROMATOGRAPHY_SUMMARY        	eluate was directly introduced to ESI source of QTRAP5500 mass analyzer
CH:CHROMATOGRAPHY_SUMMARY        	(ABSCIEX) in the negative ion mode with following conditions: Curtain gas: 35
CH:CHROMATOGRAPHY_SUMMARY        	psi, GS1: 35 psi, GS2: 65 psi, Temperature: 600 ˚C, Ion Spray Voltage: -1500 V,
CH:CHROMATOGRAPHY_SUMMARY        	Collision gas: low, Declustering Potential: -60 V, and Entrance Potential: -7 V.
CH:CHROMATOGRAPHY_SUMMARY        	The eluate was monitored by Multiple Reaction Monitoring method to detect unique
CH:CHROMATOGRAPHY_SUMMARY        	molecular ion – daughter ion combinations for each of the lipid mediators
CH:CHROMATOGRAPHY_SUMMARY        	using a scheduled MRM around the expected retention time for each compound.
CH:CHROMATOGRAPHY_SUMMARY        	Optimized Collisional Energies (18 – 35 eV) and Collision Cell Exit Potentials
CH:CHROMATOGRAPHY_SUMMARY        	(7 – 10 V) were used for each MRM transition. Spectra of each peak detected in
CH:CHROMATOGRAPHY_SUMMARY        	the scheduled MRM were recorded using Enhanced Product Ion scan to confirm the
CH:CHROMATOGRAPHY_SUMMARY        	structural identity. The data was collected using Analyst 1.6.2 software and the
CH:CHROMATOGRAPHY_SUMMARY        	MRM transition chromatograms were quantitated by MultiQuant software (both from
CH:CHROMATOGRAPHY_SUMMARY        	ABSCIEX). The internal standard signals in each chromatogram were used for
CH:CHROMATOGRAPHY_SUMMARY        	normalization, recovery, as well as relative quantitation of each analyte.
CH:CHROMATOGRAPHY_TYPE           	None (Direct infusion)
CH:INSTRUMENT_NAME               	Prominence XR
CH:COLUMN_NAME                   	Luna C18 (3u, 2.1x150 mm) column
CH:FLOW_RATE                     	0.2ml/min
#ANALYSIS
AN:ANALYSIS_TYPE                 	MS
#MS
MS:INSTRUMENT_NAME               	ABI Sciex 5500 QTrap
MS:INSTRUMENT_TYPE               	QTRAP
MS:MS_TYPE                       	ESI
MS:ION_MODE                      	NEGATIVE
MS:MS_COMMENTS                   	Mass spectra for each detected lipid metabolite were recorded using the enhanced
MS:MS_COMMENTS                   	production feature to verify the identity of the detected peak. Data were
MS:MS_COMMENTS                   	collected and quantified using Analyst 1.6.2 (SCIEX) and MultiQuant (SCIEX)
MS:MS_COMMENTS                   	software, respectively. Correction for recovery efficiencies and relative
MS:MS_COMMENTS                   	quantitation of each analyte were performed using signals from each chromatogram
MS:MS_COMMENTS                   	corresponding to the spiked-in internal standards. Under standardized conditions
MS:MS_COMMENTS                   	of liquid chromatography-mass spectrometry quantitation, the detection limits
MS:MS_COMMENTS                   	for the eicosanoids are 1–2 pg on the column and the limit of quantitation is
MS:MS_COMMENTS                   	5 pg at a signal-to-noise ratio of 3.
#MS_METABOLITE_DATA
MS_METABOLITE_DATA:UNITS	ng/g tissue
MS_METABOLITE_DATA_START
Samples	EicoT1	EicoT2	EicoT3	EicoT4	EicoT5	EicoT6	EicoT7	EicoT8	EicoT9	EicoT10	EicoT11	EicoT12	EicoT13	EicoT14	EicoT15	EicoT16	EicoT17	EicoT18	EicoT19	EicoT20	EicoT21	EicoT22	EicoT23	EicoT24	EicoT25	EicoT26	EicoT27	EicoT28	EicoT29	EicoT30	EicoT31	EicoT32	EicoT33	EicoT34	EicoT35	EicoT36	EicoT37	EicoT38	EicoT39	EicoT40	EicoT41	EicoT42	EicoT43	EicoT44	EicoT45	EicoT46	EicoT47	EicoT48	EicoT49	EicoT50	EicoT51	EicoT52	EicoT53	EicoT54	EicoT55	EicoT56
Factors	Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	Genotype:F344 Pirc | Treatment:AIN-93G (control) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	Genotype:F344 Pirc | Treatment:200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	Genotype:F344 Pirc | Treatment:LD TP-252 (1.5% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	Genotype:F344 Pirc | Treatment:HD TP-252 (3% EPA) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	Genotype:F344 Pirc | Treatment:EPA-FFA (2% EPA) | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon	Genotype:F344 Pirc | Treatment:EPA-FFA (2%) + 200 ppm Naproxen | Metabolite:Eicosanoid | Tissue:Tumor-adjacent normal colon
13,14dhPGE1			2.421	0.883	1.214	1.649	3.184						1.112		1.967	2.351	2.661	4.983		0.633	1.378	1.857	0.566	0.984	1.817	1.045	3.871	0.947						0.497										0.609		5.137		0.582	0.862	1.230	1.553					
13,14dh-15k-PGE1	1.940	2.867	4.185	4.616	5.983	3.038	4.270	2.806		1.317	6.128	1.399	5.942	2.322	2.805	2.405	2.095			1.919	3.206	1.472	1.779	1.075	2.256		2.037	2.658	2.249	1.547			1.812	2.872	2.254	0.453	1.861		0.623		0.991	1.619		1.633		2.771				2.551		1.637	1.249	0.712	0.632	0.852
D17-PGE1																																																								
PGE1	183.678	66.748	206.016	108.637	163.794	232.989	258.099	16.757	7.297	16.000	50.311	15.727	79.481	14.752	147.692	146.349	114.514	168.729		113.359	116.614	121.942	68.015	82.364	121.486	53.073	202.388	68.860	45.087	14.986	9.540	14.252	13.956	42.992	40.610		31.057	17.530	6.448	14.309	13.659	31.690	19.414	83.884	52.679	187.243	17.667	72.525	74.349	129.077	167.317	19.815	11.398	10.623	1.888	8.893
15(R)-PGE1				19.444	46.585	24.233		8.792	3.919	7.628	20.742	6.512	28.910	6.888	9.854					13.624									11.837		2.363	4.803	3.875		8.117	2.238	7.989				3.848											6.053	3.817			2.254
15-keto PGE1		0.936	1.125	1.836	3.490	2.477	1.253											1.290	0.898				2.338																											0.999	2.217					
Bicyclo PGE1	2.063	6.179	20.896	11.758	17.550	17.368	29.077				3.892				14.939	13.931	13.773	21.625		8.534	10.466	8.264	3.510	7.288	8.676	3.990	19.607	4.433																2.536	2.883	14.094	2.514	2.791	4.661	4.224	6.076					
19(R)-hydroxy PGE1																																																								
2,3-dinor PGE1																																																								
PGE2	1875.040	2393.090	3561.858	3141.265	4703.833	2677.378	2756.055	1465.824	639.674	633.195	3400.772	950.073	4083.563	1194.619	1759.598	1355.810	774.372	792.158	44.391	1674.120	1975.000	908.602	964.810	581.466	994.667	581.351	634.191	587.372	1295.638	740.582	327.074	878.178	850.007	1605.663	1134.390	188.227	1192.255	689.017	231.180	344.491	569.962	700.220	167.478	871.405	611.997	922.745	220.253	652.771	706.190	1260.751	1287.408	877.566	564.397	460.595	88.547	324.990
15-keto PGE2	32.219	97.408	114.124	146.991	247.302	130.184	86.022	24.623	7.234	20.088	85.536	25.267	37.609	43.586	34.805	45.324	41.758	65.912	2.268	60.982	55.147	11.230	46.812		32.334	17.315	19.421	30.723	21.976	16.138	4.784	10.476	32.562	22.619	16.043	2.244	8.995	11.710	4.744	14.424	9.425	8.119	5.067	30.667	52.898	23.442	29.754	52.100	37.343	86.629	107.833	9.926	13.240	8.387	3.405	12.216
13,14dh-15k-PGE2	145.088	186.355	370.070	232.735	446.164	346.205	419.213	65.231	35.317	25.064	173.706	43.583	187.354	51.497	296.025	232.185	156.412	184.760	4.316	165.606	243.978	99.072	87.634	62.692	140.962	79.704	174.254	110.280	56.451	31.965	13.186	34.619	34.729	71.834	49.351	10.281	54.241	27.382	10.122	14.421	30.190	30.079	28.598	90.619	76.715	197.002	40.660	106.389	152.988	161.660	189.345	39.402	22.590	24.469	5.908	14.424
Bicyclo PGE2	13.215	21.261	41.639	32.182	44.581	23.600	58.211	4.563	3.286	1.345	34.797	6.300	24.482	2.312	11.781	12.543	41.365	12.766	0.928	19.010		8.611	8.520	11.483	8.159	4.620	15.567		8.152	3.836	1.193	3.795		8.669	5.497	0.725		2.585	1.418			2.859	3.171	4.842		10.342		4.999	4.321	10.724	8.075	5.218	2.021	3.131		1.562
PGA2	552.984	875.903	1085.115	1242.335	1678.129	842.251	1089.647	138.729	68.177	51.015	893.551	159.577	448.045	185.171	395.804	359.853	686.869	424.337	6.027	527.850	518.546	291.589	282.043	336.272	389.296	152.164	506.088	116.984	244.424	83.449	21.918	49.291	51.134	258.164	187.525	12.506	122.244	50.800	19.051	39.306	66.034	105.615	147.976	161.574	144.327	396.815	65.790	178.244	229.097	435.662	476.119	131.850	41.156	60.338	7.684	35.435
tetranor PGEM	0.497	0.432		0.331	0.440	1.437		0.484	0.405		0.528	0.481		0.744	0.395	0.637	0.688	0.734	0.781		0.431	0.745	1.017	0.514	0.558	0.716	1.485	0.431	0.497	0.272	0.315	0.537	0.497	0.485	0.392	0.241	0.410	0.405	0.405	0.353	0.574	0.523		0.393	0.786	0.444	0.980	1.033	0.222	0.661	0.502	0.281	0.392	0.797	0.355	0.319
PGE3	6.820	6.215	12.864	11.356	28.205	7.562		10.152				1.864		2.474	131.192	96.837	72.107	134.170	16.144	169.180	212.802	241.806	398.602	127.140	136.667	109.745	333.840	165.105	83.507	77.278	13.487	49.646	52.810	135.658	51.062	46.945	215.639	93.873	34.945	117.026	105.850	99.844	15.145	138.040	90.146	128.564	28.212	36.826	77.520	81.733	56.273	90.306	46.370	68.919	17.310	21.289
PGD2	3627.597	4069.674	4080.768	3912.282	6317.116	3986.568	4952.696	434.007	261.696	172.713	3024.784	899.383	1614.471	693.456	1842.116	2192.430	3139.806	2402.866	30.795	2249.442	2283.037	1620.525	1571.215	1496.542	1880.052	791.328	2598.025	892.938	1593.996	456.559	99.909	163.040	200.790	1532.921	1157.149	34.717	556.273	290.856	93.597	265.565	376.581	689.160	1315.680	1157.450	856.902	2261.584	460.286	1236.769	1487.741	2674.384	3043.166	693.529	198.115	295.568	36.573	206.962
PGJ2	493.159	762.720	883.443	1125.593	1380.745	656.883	893.884	92.931	45.823	29.558	708.382	127.257	285.197	133.087	303.062	305.036	580.219	361.734	5.180	435.781	435.957	247.692	245.267	283.183	325.557	126.266	446.013	101.674	187.078	57.667	12.412	29.517	31.672	202.598	134.226	7.511	83.157	35.379	13.242	28.868	47.220	79.350	125.653	136.483	111.932	324.885	55.651	146.570	193.790	372.913	404.985	96.049	28.840	41.783	4.920	25.673
D12-PGJ2							237.441		13.213	6.605		37.517	61.735	29.310		82.545	117.167	92.247			108.393		69.847				94.901					8.282	9.251						4.277				48.247					49.240			132.934		7.981		1.695	7.348
15d-D12,14-PGJ2	5.720	14.529	18.762	31.869	25.421	11.573	18.378	1.143	0.605		18.682	2.621	4.640	2.011	6.397	6.012		11.502		13.676	6.522	6.803	10.904	8.778	6.553	2.998		2.163	4.711					4.366	2.852	1.106					2.719			2.105	2.747	4.616		1.857	2.232	4.873	5.596		1.397			
13,14dh-15k-PGD2	224.692	273.568	442.405	295.923	358.915	179.786	735.599	36.721	17.737	27.743	198.602	27.368	101.515	34.762	121.929	117.439	340.466	154.569		154.852	109.797	100.101	98.317	108.595	118.766	43.389	168.750	55.520	64.635	28.606	10.563	23.049	29.006	68.368	37.143			27.264		21.281		30.396	51.783	51.226	56.196	238.591	22.573	62.284	83.519	132.766	133.866	53.382	29.417			15.701
PGD3	8.083	20.467	24.902	31.521	54.838	30.411	20.270			4.316	19.759	4.890	9.960	6.545	53.639	42.341	120.405	112.735		122.698	69.712	174.373	190.379	111.083	75.618	60.054	411.774	84.110	64.263					45.568	27.254			39.906		51.146	40.287	71.644	54.819	49.300	52.709	210.926	22.864	32.494	67.757	52.195	36.438	43.676				9.963
15d-D12,14-PGJ3			20.613	22.342			20.266				15.012									12.309	3.806																																			
PGF1a	4.481	2.437	7.858	4.533	7.644	5.506	6.099	4.755	2.505	2.278	7.272	1.704	11.004	3.859	4.826	6.143	2.399	6.881		3.624	6.927	4.996	5.465	2.468	5.554	2.430	7.885	3.394	4.281	3.320	3.119	4.751	5.787	5.647	4.395		4.696	4.760	1.260	1.119	2.404	4.254		3.055	2.335	6.982		2.471	3.028	6.834	5.564	2.837	2.929	1.942	1.382	1.079
PGF2a	160.766	171.657	247.735	319.138	361.355	239.330	308.913	180.312	93.141	107.984	446.571	97.040	346.586	124.908	147.368	147.158	84.406	148.187	4.297	91.969	177.719	82.508	116.227	73.145	112.958	48.799	137.897	72.262	138.934	100.383	75.720	116.256	125.079	188.820	122.723	34.240	123.970	96.228	38.645	38.504	84.312	91.020	12.720	79.561	66.884	161.668	40.426	46.633	90.951	149.690	141.499	114.508	60.869	57.027	36.851	41.356
15-keto PGF2a	95.258	130.690	217.229	153.397	270.005	172.979	174.247	68.901	31.228	31.987	168.606	46.455	199.343	58.029	128.145	97.232	58.175	76.163	2.057	94.279	125.652	51.745	49.480	31.854	67.555	36.132	58.274	45.653	56.732	33.289	15.738	39.252	43.724	77.218	54.202	8.147	58.720	29.945	10.891	15.934	30.417	30.645	10.408	52.238	45.500	74.897	18.212	44.580	60.369	86.120	93.047	41.118	23.882	22.414	5.209	18.166
13,14dh-15k-PGF2a	6.016	8.406	17.643	23.548	33.289	25.917	42.554	6.909	1.921	3.625	24.482	3.697	8.929	4.156	19.672	21.803	14.804	37.875		9.419	27.552	18.538	11.626	11.731	34.608	5.156	32.754	14.011	7.218	3.215		2.888	4.764	7.355	3.002			2.978			4.135		2.921	8.240	9.701	38.298	11.625	7.048	20.402	33.150	37.024	4.941	2.555	2.552		1.324
PGF3a															2.907	2.770	4.766	6.569		3.782	4.557	8.766	13.192	8.373	4.134	3.220	14.502	5.502	4.069	4.705			2.843	6.530	2.497	2.322	6.410	5.049		3.640	4.543	5.237		3.478	3.883	9.079			3.241	2.586	2.025	5.010	1.151		1.196	
iPF-VI			1.513	2.542	2.147	1.006					3.711	0.723					1.808								0.835											0.536										0.531										
6kPGF1a													191.426												125.559			72.723			69.677					13.985				9.447				76.063										13.570		
6-keto PGE1																																																								
6,15-diketo PGFa		6.771	12.824	10.345	22.292	10.134	35.687				1.006				25.290	18.012	21.972	24.373		5.716	21.203	16.174	8.346	12.487	19.985	13.429	6.107	17.664															2.712	10.962	14.505	25.390	12.924	9.737	17.705	15.795	17.027					
TXB2		164.102		353.927	514.944	316.322		136.120	45.984	55.796	626.051	87.069	519.458	78.172	194.476	173.719	93.176	124.082	8.243	118.771	221.827	155.750	65.241	85.099	125.722	72.330	119.370	76.091	170.654			77.552	104.161	191.206	110.726	15.155		55.875			57.338	80.116	16.913	97.572	59.977		19.902		99.349	125.244	166.717				16.433	
11dh-TXB2	4.361	4.332	7.328	24.800	8.539	5.075	8.852	4.334			46.743	2.208	9.686		2.404			7.282		1.695	2.327	2.008	4.057	2.001	1.535	1.289		1.512	7.824	3.026	1.519	3.164		9.417	3.282		2.856	1.416			1.781	1.546				1.873		1.270	1.215	2.495		5.255	1.840			
2,3-dinor TXB2																																																								
11dh-2,3-dinor TXB2																	4.899	2.056	4.157						4.328				0.841							0.611	0.708				0.708	14.330														
TXB3			1.511			2.266	2.536								13.157	18.962	15.708	21.108	6.305	16.961	19.287	54.959	23.296	25.903	17.540	14.434	81.995	21.687	12.901	10.891	0.985	1.831	2.877	14.833	4.916	2.439	11.965	7.212	3.073	9.547	12.185	12.726	5.228	12.248	8.173	41.032	4.598	2.235	14.472	7.742	7.300	13.162	1.903	4.987		2.486
11dh TXB3	2.924	6.701	3.980	4.048	9.430	4.561	7.893	1.294	0.681		7.930			1.172	1.374	2.400	4.234			5.276	3.169	1.894	7.929	3.717	0.952				2.088	0.680																										
LTB4		4.059	11.892	7.854	7.861	7.290	14.740	6.987	2.709	2.472	17.910	3.707	13.622	6.516	1.030	1.091	1.849			3.070	1.492	3.213		1.700	2.487	0.487		1.351	2.010	3.832	1.944	2.047	2.816	5.597	2.859	0.778	1.805	1.881	0.834	0.955	1.086	3.209		0.841	0.661	2.370				1.479		5.255	1.587	2.145	0.249	0.824
12-OxoLTB4								1.779	0.468								0.484							1.215				0.506		0.815	0.290		1.069			1.558	1.002	0.837		1.802		1.270			0.637	1.079						1.719	0.964			
20-hydroxy LTB4															0.108																							0.071																		
20-COOH LTB4																						0.089		0.068																															0.032	
18-carboxy dinor LTB4						10.453						6.055	10.947						19.593	18.473					11.354										6.684								6.954													
LTB5	0.528		1.008	2.129				0.615			2.444	0.289	0.954		1.435				0.863				6.797	2.568		4.065	3.977					0.475				1.309	1.940		0.969	2.682	2.748			0.238			0.394		0.341							
5(S),6(S)-DiHETE													0.963				1.046										0.372		0.333																											
5(S),12(S)-DiHETE	2.639	6.085	2.212	2.137	4.016	11.112	3.296	4.020	1.160	1.537	3.897	2.770	3.375	2.177	1.551	1.596		0.842	1.646	1.925	1.719	0.741	2.178	0.617	1.058	2.376		0.750	0.919	0.341	0.821	1.373	3.082	0.784	1.218	5.978	4.697	0.691	0.695		1.172			0.867	0.757	0.380	0.765	1.588	0.763	1.102	1.342	1.206	1.631	1.759	0.317	0.908
5(S),15(S)-DiHETE		0.437	1.176	1.737	1.842	1.359			0.383		2.381	0.285					0.537			0.927				1.500	0.572					0.386						0.610	0.586	0.401		1.303	1.468	1.198	0.405	0.523	0.880	1.724			0.487	0.404		1.917		1.154	0.224	0.280
8(S),15(S)-DiHETE			1.758		3.786	5.313	2.486			2.589			3.337		1.053		1.804					1.185		1.122			1.538		1.538	0.908			1.570	1.666	1.134												0.530	1.127	1.001	1.043	1.540	1.305	1.046	1.322		0.686
5(S),15(S)-DiHEPE	3.511	3.421	4.908	13.770	16.187	3.073	5.799	4.136	0.882	1.605	15.727	2.815	5.525	1.472	5.021	1.663	4.227	8.332	1.723		1.799	9.972	14.879	6.684	5.985	4.683	16.125	5.605	4.047	2.711		1.213	2.932	6.139	2.000			3.195	1.974	1.782		5.730	0.993	1.098	2.094	6.364			1.284	2.295	4.100	5.156	0.951	1.790		0.699
9-HODE		938.930				660.998	607.719	518.793		156.329		186.714		296.143		448.318	3512.980	3876.273	758.303	733.493		766.473	1763.611	787.123			4050.329	589.937		462.405	374.127		439.884		561.560	520.731	546.440		201.270	543.238	418.993	544.108	306.664		673.842	369.552	1474.731	1210.566	257.272	565.420	250.748	548.580	366.299		97.361	210.908
13-HODE	4511.916	11135.674	6933.437	9321.018	10456.298	11105.600	9919.975	6110.768	5480.018	1715.088	10184.317	1845.013	7052.243	3123.880	3319.328	6068.308	23115.789	22794.409	5057.705	7360.252	6493.589	7125.944	15094.013	6163.345	6792.483	3740.730	33757.252	6254.636	5407.258	5234.955	2764.665	6018.620	4724.437	5951.584	5363.441	3983.522	5126.983	5278.068	2272.182	6300.298	4069.130	5125.498	2035.170	5168.347	7763.852	5469.969	8953.103	6604.760	2744.222	6890.663	3023.780	5232.458	3170.003	2120.087	1016.622	1924.068
9(S)-HOTrE	46.967	188.191	40.007	104.377	57.517	82.532	38.261	64.036	54.163	35.064	73.493	13.890	35.167	21.284	15.968	56.816	413.522	932.880	125.523	71.160	38.535	55.452	209.232	74.056	61.888	71.583	1264.570	96.489	41.421	65.586	18.554	50.640	53.359	47.396	45.269	88.222	67.989	52.214	34.816	106.688	45.550	42.273	42.219	34.167	82.726	42.167	149.054	43.480	27.833	58.438	25.884	46.601	30.010	34.308	16.646	25.244
13(S)-HOTrE	117.491	331.342	100.767	111.648	96.609	971.523	73.399	371.182	116.578	29.922	125.667	47.504	67.407	57.681	30.814	78.540	555.465	953.305	138.370	86.285	68.468	54.217	299.979	65.382	85.708	111.276	1217.779	151.172	33.580	78.172	26.994	68.195	123.430	76.428	49.335	77.936	58.765	81.506	57.462	174.081	77.695	78.591	39.714	64.648	94.783	68.326	173.226	73.265	27.625	94.350	37.733	124.948	61.097	32.707	24.018	61.627
13(S)-HOTrE(g)	16.493			28.875	43.094	28.290		10.622	12.344			17.763					72.703	152.452	15.902	23.919	13.008	13.528	29.415		9.905		108.547	14.433	22.628																							20.593				
11(R)-HEDE	51.718	117.743	163.034	217.592	212.658	139.708	299.904	43.487	44.469	22.379	168.605	18.865	129.879	44.544	55.539	94.780	256.966	151.956	14.954	185.009	115.604	94.798	172.469	75.389	93.854	43.238	199.756	51.579	84.694	38.519	50.051	59.997	39.948	68.173	49.570	11.300	35.557	31.651	13.553	29.114	40.378	47.262	5.072	66.789	83.110	71.346	37.854	46.871	43.361	60.023	37.279	46.862	23.265	19.129	3.461	10.755
15(S)-HEDE	10.687	18.054	23.860	35.583	30.158	28.360	40.275	12.012	8.517	5.730	31.705	6.425	26.920	9.454	8.425	10.297	34.704	23.418	5.518	24.663	12.590	18.394	33.915	16.374	11.408	7.712	28.153	9.227	20.931	7.729	7.245	10.946	9.386	12.594	11.469	3.272	8.588	7.334	4.861	7.318	12.543	10.018		9.362	14.608	9.384	9.353	6.819	5.406	6.985	5.534	12.150	6.057	4.838	1.186	3.937
8(S)-HETrE	72.214	44.767	131.166	101.594	62.458	120.694	52.339	27.435	18.545	22.581	127.583	26.781	76.944	36.264	18.927	43.776	70.452	38.097	9.732	104.969	36.552	128.023	136.709	93.135	37.445	27.401	55.712	60.594	80.385	25.325	33.005	35.855	47.501	56.961	51.557	26.081	51.844	26.533	23.031	29.395	60.520	54.528	7.245	32.969	52.828	22.928	29.104	49.258	26.352	32.271	29.954	39.106	36.103	35.591	7.549	16.344
5(S)-HETrE	0.784	3.058	2.270	4.196	2.505	4.034	2.773	1.480	0.899		4.105	1.010	2.477	1.037	0.985	1.306	3.923	6.361	0.806	1.940	0.625	3.005	3.632	3.665	3.031	1.240	14.236	3.163	2.722	0.976	0.892	1.152	0.990	1.648	1.636	1.301	1.687	0.837	0.711	3.025	3.204	1.473	0.335	1.028	1.734	1.170	1.300	1.970	1.068	1.530	2.092	1.978	1.222	0.795	0.314	0.868
5-HETE	511.908	655.037	1804.375	1708.099	1225.617	1880.130	2112.801	572.505	481.625	308.778	3340.661	535.006	1583.222	635.012	219.156	382.035	727.008	405.809	134.290	793.785	372.288	606.166	779.838	438.249	321.093	192.182		476.992	692.506	241.010	358.163	376.590	331.965	574.398	518.274	204.698	414.339	222.529	163.291	190.837	444.453	387.882	52.612	234.819	386.358	284.173	203.400	461.079	215.886	260.831	236.918	580.530	305.284	251.369	58.754	153.043
8-HETE	308.792	366.550	328.489	439.922	394.680	679.138	453.274	139.071	143.274	249.288	784.840	181.299	309.995	137.432	65.160	112.084	160.663	106.021	35.192	228.674	92.328	157.348	254.003	162.572	78.923	72.001	114.327	74.773	234.434	63.875	123.481	107.090	111.714	137.931	125.144	57.503	79.887	60.914	52.526	59.228	148.651	125.310	16.801	81.493	121.046	62.539	75.805	187.042	57.071	69.335	76.012	135.942	99.150	84.514	17.581	51.325
9-HETE	83.173	102.028	157.107	253.318	246.214	278.856	230.916	72.370	66.115	65.712	385.650	83.709	177.609	73.303	35.183	62.894	111.430	68.388	19.837	120.150	58.733	98.373	134.416	88.382	48.020	35.216	127.770	42.282	140.253	31.531	57.699	53.008	54.859	87.985	70.242	30.999	45.783	38.983	23.543	43.861	89.201	69.251	7.873	43.538	70.967	34.981	37.536	84.342	30.306	45.892	45.199	66.700	59.728	40.759	10.352	27.064
11-HETE	8116.597	13828.873	16858.887	17937.026	24830.454	19864.782	25185.254	8229.152	8049.360	6373.437	24777.698	6122.861	23035.131	6386.365	9593.989	12320.719	16094.317	8260.991	708.352	13604.013	11355.307	9055.400	11415.088	6476.242	9881.193	5970.936	11259.425	7172.180	10506.431	4338.514	5657.770	7644.838	5973.742	9714.269	7526.432	1342.495	6452.864	5811.450	2725.743	2651.908	5986.755	7383.433	732.283	8351.254	8079.401	8390.419	4349.973	8274.464	6555.821	10839.778	8392.269	6775.027	4026.487	4026.764	578.446	2712.042
12-HETE	1311.580	3205.259	1772.693	1804.016	1719.160	6338.294	3538.014	1645.670	1257.553	785.395	2696.668	1418.320	4115.201	1090.597	916.689	1096.934	727.654	501.834	583.392	1267.392	1086.295	554.643	934.619	605.072	737.194	1008.737	311.205	661.756	811.170	209.909	987.399	842.890	1081.086	509.879	821.665	1707.024	1653.954	439.728	469.844	125.296	687.250	691.927	39.149	659.897	531.561	219.368	532.916	1214.078	391.710	722.527	573.852	817.535	602.019	704.723	164.807	624.658
15-HETE	1613.512	2535.908	4063.143	3350.897	4384.314	5855.991	5710.632	2056.442	2002.149	1540.604	6790.984	1751.055	5634.986	1814.162	1883.968	2559.893	2466.174	1186.712	211.955	2426.772	2275.926	1803.946	1722.884	1313.875	1355.756	1096.322	1412.562	1482.406	2401.449	755.371	1332.980	1684.875	1495.736	1821.155	1965.107	430.537	1355.400	1268.269	618.926	410.614	1383.167	1627.383	138.597	1614.389	1480.037	1544.120	852.551	1796.715	1159.497	1799.376	1606.695	1517.511	1067.748	857.515	160.340	646.050
20-HETE	151.374	147.453				187.789		109.633	68.349	81.146	373.095	66.208	169.571	61.103			180.228	500.543	48.067		63.583		315.818		49.590		1463.083	60.580			82.452	60.011	95.436							134.920	87.847	65.616	23.004	58.214			82.779	104.468					42.191		9.158	30.183
tetranor 12-HETE	8.591	4.345	10.088	9.868	7.555	12.963	5.256	3.234	6.072	3.973	11.240	3.835	14.305	2.053			4.910	9.814	1.453			2.056	3.963		6.030	2.983	14.874	2.881	1.593	1.027		1.400	2.259	5.114		3.040		2.787	1.249	2.787	2.628				1.735	1.491			1.086	2.029		3.019	4.990	1.293	1.550	2.437
12(S)-HHTrE	1551.547	1963.997	2810.843	2493.586	5820.007	2250.186	3146.462	2458.420	1402.392	1641.120	7196.304	1704.888	5502.427	1777.719	1821.428	1525.832	1036.626	573.224	41.141	1152.366	1756.041	963.636	1556.081	736.572	1391.135	790.046	957.896	1018.678	2304.167	1688.718	703.106	1708.961	2029.238	3402.622	2112.106	380.060	1402.579	1576.209	686.739	590.716	1414.585	1466.509	96.877	1467.729	1031.005	1440.456	332.765	810.014	965.704	1410.469	1152.688	2278.499	1065.618	1174.585	262.428	836.529
5-HEPE	20.873	18.752	45.826	27.962	22.799	56.063	55.220	39.617	20.033	7.924	100.383	12.503	23.657	9.051	134.354	276.526	2531.296	8051.518	396.746	446.364	173.925	1977.844	2679.115	1672.889	468.802	527.776	22514.429	1121.873	796.168	553.932	127.609	242.924	214.260	591.481	358.226	887.427	1080.292	813.873	473.945	2839.110	1809.111	994.130	366.044	205.335	774.097	742.623	637.455	168.609	227.525	249.943	125.156	1662.130	292.129	320.466	82.237	205.642
8-HEPE	22.561	10.838	7.561	15.419	10.279	16.461	12.873	7.996	13.643	5.497	29.805	4.143	7.669		53.118	79.527	366.528	1248.643	137.472	180.831	61.565	461.807	962.282	586.634	163.973	288.763	3071.303	371.113	261.345	112.752	47.940	79.848	97.070	190.121	102.936	245.966	269.583	210.789	210.172	471.812	473.354	273.504	53.195	71.579	240.724	119.035	194.459	69.485	59.722	44.063	31.338	269.697	109.658	122.472	28.573	79.101
9-HEPE	7.926		6.262			14.432	7.878	8.598	7.223					5.152	28.453	51.914	322.525	863.473	81.017	124.502	31.225	345.556	724.849	386.855	116.825	159.403	1724.007	212.885	202.975	102.659	31.144	48.226	62.661	142.845	65.840	144.279	202.438	178.648	152.222	503.221	418.344	194.552	41.722	47.880	180.900	106.907	101.461	42.528	43.887	34.749	26.093	205.524	65.508	67.600	16.971	51.014
11-HEPE	114.691	152.975	202.369	211.874	354.176	205.891	185.505	120.386	45.120	35.318	214.515	26.186	80.605	24.435	1209.526	1485.871	3445.886	4856.138	416.246	2337.833	1568.848	5026.694	8425.649	3902.139	3038.925	2027.616	14167.142	3105.908	2608.094	1353.065	488.617	802.129	852.824	2391.867	1099.110	749.864	2372.110	1991.308	912.816	2653.039	2957.719	2506.585	287.122	1475.296	2696.151	3205.713	1047.313	704.849	1253.066	1048.137	687.897	2144.569	742.649	611.071	163.265	456.156
12-HEPE	59.124	106.837	61.317	67.952	60.193	200.381	90.718	87.609	102.661	18.533	97.534	41.396	63.389	18.785	689.025	835.660	1162.363	3077.424	1865.790	903.514	663.412	1539.224	3898.264	1544.211	1602.844	2024.563	6666.660	2032.264	794.411	413.520	333.535	455.279	887.714	729.115	561.101	2767.477	3012.415	1214.845	1037.653	1064.078	1658.013	1553.424	137.078	763.345	924.110	533.311	1040.385	599.066	429.001	494.956	300.539	1858.290	786.934	695.259	287.240	811.643
15(S)-HEPE	46.800	58.123	53.834	86.450	82.978	163.384	79.194	55.496	61.646	10.302	110.767	21.676	40.575	15.146	416.273	534.825	2161.619	4924.803	493.327	805.774	481.625	1734.538	3899.241	1533.911	950.228	1573.479	14623.653	1675.035	817.925	478.111	191.009	284.343	537.199	804.995	506.127	567.055	807.607	853.826	661.864	1692.521	1638.192	1250.372	188.004	555.207	934.604	798.647	732.872	370.457	322.085	313.295	219.905	1497.024	438.125	324.676	122.009	442.485
18-HEPE	66.126	26.440	40.316	71.741	68.714	69.044	48.576	35.425	25.266	12.631	110.189	20.737	30.481	10.075	267.564	337.611	955.435	1989.176	316.221	441.132	251.720	1853.678	2889.525	1784.018	711.341	602.816	5564.564	964.194	992.358	406.962	158.116	274.399	302.335	767.287	413.219	468.584	744.474	757.747	462.586	1140.660	1377.305	1036.738	121.982	297.288	733.468	635.360	420.658	241.993	273.668	239.794	207.070	1043.852	400.236	385.835	116.032	258.622
4-HDoHE	40.433	45.977	47.825	81.393	43.566	55.492	44.005	34.640	22.571	13.421	101.307	16.852	46.654	20.160	12.725	32.272	76.380	121.025	58.917	70.265	46.080	44.530	266.845	69.939	33.799	18.622	217.579	58.239	39.645	21.211	33.535	34.878	31.806	28.884	28.995	60.699	44.778	20.425	18.131	28.217	48.321	25.631	12.243	28.607	47.300	15.926	95.531	73.183	25.048	25.907	20.294	38.082	31.698	15.174	15.445	11.983
7-HDoHE	6.221	10.846	11.573	18.202	10.092	12.887	15.166	5.295	4.558	4.549	15.970	4.186	9.977	5.356	3.666	6.411	15.317	20.998	3.906	10.197	5.651	12.132	28.301	13.399	6.747	4.342	41.375	5.406	8.221	5.049	7.851	6.565	5.651	6.542	6.676	9.377	8.250	3.498	5.893	4.144	11.156	5.560		8.794	9.193	3.859	16.119	16.962	4.078	5.910	5.063	5.768	6.923	3.412	2.372	2.684
8-HDoHE	13.273	23.558	20.738	35.330	20.081	24.297	16.930	12.388	9.008	8.221	33.049	9.712	23.597	8.311	5.865	16.991	41.981	65.436	24.086	27.487	17.686	18.708	91.653	30.582	14.334	11.520	122.846	16.552	23.463	10.947	17.066	16.992	15.542	14.584	12.019	23.759	20.240	11.022	11.821	19.027	25.501	13.845	6.334	16.701	25.744	7.805	42.158	29.733	9.594	11.230	11.684	12.508	13.956	9.861	6.529	4.682
10-HDoHE	49.001	69.220	29.494	51.796	35.439	49.674	36.369	16.355	12.138	27.412	55.149	13.936	30.263	14.188	10.890	22.664	53.131	85.970	24.321	32.322	23.467	34.712	92.932	37.163	22.106	19.307	177.310	29.466	27.852	12.648	16.778	22.805	21.079	18.242	20.112	31.495	25.577	18.414	15.173	24.620	35.218	24.785	9.067	18.595	39.223	13.456	45.206	42.964	16.626	17.859	16.021	27.438	24.247	11.965	7.773	10.534
11-HDoHE	14.684	31.010	24.336	44.783		36.939		12.725	11.023	11.948	42.162	9.948	18.374	10.818		18.498	41.424	65.825	19.877	29.144		19.286	78.122	28.824		13.844	137.743	21.500	26.554	11.594	13.623	19.101	19.135	15.731	18.075	30.741	25.109	13.258	12.656	19.323	25.039	12.948	6.539		30.376		34.406	30.230	10.645	13.000	13.015	14.341	13.930	9.522	7.516	7.826
13-HDoHE	100.128	199.320	246.780	276.942	380.192	344.590	398.089	62.883	66.832	56.539	141.102	44.993	162.227	40.156	123.959	214.726	440.680	237.430	40.406	291.590	218.102	188.175	280.975	133.918	182.553	118.401	665.299	151.933	71.716	33.400	79.291	87.485	64.302	56.033	55.803	85.067	111.098	63.165	47.210	44.626	67.685	60.808	19.664	202.757	172.515	179.483	135.863	200.814	107.473	177.934	117.561	47.740	43.337	64.299	16.952	26.916
14-HDoHE	102.190	176.369	109.036	111.607	96.118	408.437	239.854	60.820	34.902	35.490		66.500	91.920	39.303	54.835	95.093	100.383	137.858	65.941	128.066	71.841	80.544	197.085	66.137	66.250	103.453	239.553	90.600	42.090	23.019	39.727	42.512	51.626	50.423	61.223	53.810	57.387	53.459	45.613	36.375	99.720	67.324	13.274	70.318	73.038	35.943	110.649	118.263	32.467	47.244		93.814	47.538	33.953	12.563	43.685
16-HDoHE	60.260	99.480	88.890	107.606	122.737	175.341	125.275	37.394	36.790	32.124	106.311	38.226	79.292	27.744	41.104	89.489	175.223	121.516	43.055	120.401	85.323	91.140	152.477	82.897	64.888	33.307	230.416	62.123	73.654	21.167	51.398	37.921	47.491	43.789	44.166	59.124	69.536	37.598	34.840	30.858	62.419	46.460	20.864	63.123	91.086	62.920	120.746	132.908	50.894	76.465	66.608	39.351	42.624	27.499	16.331	22.202
17-HDoHE	25.569	54.574	35.716	21.366	18.493	157.669	89.460	26.846	23.545	14.522	35.563	30.059	30.657	18.990	24.450	28.437	38.344	33.613	10.491	26.702	27.482	14.851	24.942	12.297	13.951	24.448	61.194	29.188	6.250	5.602	17.305	14.232	20.466	8.404	15.557	14.805	18.503	20.011	16.663	8.779	23.266	22.133	3.597	24.604	12.968	14.709	33.281	39.467	11.716	20.280	17.660	29.557	13.105	9.656	4.888	14.000
20-HDoHE	69.095	93.868	103.062	169.913	128.668	162.241	126.661	50.574	41.958	30.108	147.941	41.514	109.198	37.575	48.555	90.894	132.639	121.359	61.347	120.274	89.241	113.006	233.310	96.878	78.365	39.970	255.762	86.964	82.483	32.992	56.560	60.621	49.617	65.787	62.875	90.703	97.567	48.827	35.062	44.690	74.730	55.896	20.832	70.583	102.730	57.102	124.147	131.311	51.214	77.854	72.241	63.140	65.618	30.290	31.565	31.972
9(10)-EpOME	51.458	170.024	41.020	67.265	48.483	61.648	68.771	81.290	49.563	24.372	136.679	26.326	51.444	42.018	34.142	56.044	1025.445	1114.942	152.626	158.281	53.346	64.310	424.293	96.462	42.966	38.709	1016.329	54.863	56.329	90.779	35.077	63.216	85.822	46.672	40.730	75.900	35.757	44.940	30.349	113.897	62.661	61.510	82.357	48.296	196.354	47.433	275.551	67.001	40.639	68.619	38.926	58.101	46.411	44.367	21.490	29.706
12(13)-EpOME	23.293	74.847	18.063	31.953	24.698	26.820	32.224	38.961	24.662	14.795	70.053	13.752	20.592	21.118	17.236	27.424	524.985	629.362	76.527	73.992	24.572	27.589	198.600		19.443	18.719	536.221	28.264		47.791	17.326	30.541	48.305	21.847	20.317	38.616	17.844	21.251	15.267	56.291	30.920	33.599	42.756	25.794	106.907	24.330	144.503	33.020	22.205			27.333	24.614	21.536	11.747	14.921
5(6)-EpETrE	10.818	9.222	12.848	14.217	16.295	23.569	20.449	11.029	7.635	5.050	35.971	7.899	11.625	8.966	2.966	5.017	13.229	6.490	3.416	16.293	4.894	5.368	17.695	7.134	3.155	2.801	4.903	6.877	11.489	3.724	6.514	7.291	7.767	6.581	6.517	4.577	5.102	3.673	2.858	3.611	6.472	5.892	1.741	3.831	8.994	2.852	5.767	8.683	3.825	4.019	3.542	4.976	4.335	4.636	1.034	2.752
8(9)-EpETrE							8.186	7.418			16.511												8.966		1.631												2.750							5.075												
11(12)-EpETrE	24.302	33.636	15.639	13.852	19.619		34.198	42.873	25.875	17.340	90.126	30.814	32.089	32.765	8.268	21.123	40.012	13.411	15.202	58.920	21.585	14.800	67.391	29.406	8.691	11.520		9.683	13.461	6.679	27.530	15.968	26.389		9.511	12.734	10.406	8.971	7.220	10.120	22.862	12.861	6.953	8.184	30.075		25.522	40.273	9.536	12.128	16.537		14.892	15.393	3.335	11.010
14(15)-EpETrE	15.078	12.298	12.225	15.085	15.214	22.384		15.462	11.004	6.506	39.136	11.827	17.816	11.574		7.244	15.384	9.376	4.453	25.084	7.122	5.721	21.543	10.445		4.086		3.154	8.246	2.646	9.175	8.296	11.971	4.848	4.448	3.158		3.557	4.221	3.907	9.101	5.491	2.176	5.990	11.946		7.368	14.634	3.465		7.248	4.639	7.459	4.025	1.518	3.818
8(9)-EpETE																0.683	3.875	7.326	4.656	2.851	0.682	7.014	9.591	10.154	1.018	2.476	14.583	1.482		1.593	1.212		1.883	1.516	0.948	1.462	1.237		2.013	4.170	6.215	2.745		1.249	4.301	0.877	3.874		0.877		0.878	1.505	2.069			0.769
11(12)-EpETE														1.348			42.234	104.910	12.231	24.112			109.650	78.751		31.716	205.391	38.316	42.474	16.566	6.540	10.529	16.502			31.200	45.624	38.757	30.794	97.226	72.813	39.878	10.194		34.247		15.964					39.234	15.325	18.278		10.719
14(15)-EpETE	7.844	7.777	9.778	6.306		19.719	14.003	9.091	4.167	4.947	30.024	10.622	8.598	10.002	2.809	3.657	4.982	22.173	4.310	10.450	4.571	12.983	35.209	17.421		3.295	44.633	4.717	6.348	4.358	2.765	2.853	6.760	6.108	4.639				2.965			3.992		2.669	8.817		4.224	5.162		3.158	5.947	4.612	4.658	5.573		2.630
17(18)-EpETE	1.244	0.654	0.878	1.000				0.657			1.999				4.947	5.050	25.005	84.910	6.564	13.315	3.405	39.253	62.781	43.440	6.803	9.712	136.449	7.989	16.866	5.622	3.039	4.372	8.529	10.519	4.679	7.517	10.864	10.946	7.020	20.926	28.870	20.255	2.827	4.960	17.860	9.282	10.610	4.495	4.188	4.005	4.603	12.172	6.773	6.681	1.832	5.572
7(8)-EpDPE	0.871	1.347		0.647	0.688	1.038	0.894	0.910	0.356		1.622	0.388	1.044			0.729	1.276	1.643	1.286	1.388	0.704		3.468	0.848	0.477	0.451	2.068	0.473	0.405	0.563	0.694	0.535	1.222			0.620	0.912		0.410	1.040	0.614		0.346	0.630	1.550	0.494	2.385	0.986	0.480			0.446	0.441		0.379	
10(11)-EpDPE	3.695	4.784	1.529	2.142	1.683	4.758	2.376	2.947	1.614	1.180	5.191	2.358	4.833	2.336	1.429	3.543	7.818	4.155	3.248	4.438	4.588	2.585	10.531	2.822	2.142	1.678	10.523	1.125	2.426	1.634	2.416	2.434	3.020	1.069	1.821	3.622	2.715	1.342	1.504	2.866	2.589	2.623	1.864	3.261	4.666	1.001	10.280	5.020	2.177	1.659	2.016	1.323	2.737	1.901	1.177	0.724
13(14)-EpDPE	1.690	1.999		2.072			1.266	2.281		0.763	3.684	1.122	2.246	1.350				1.949	3.114	1.542	1.129	0.937	5.587	2.366	1.281	0.573	2.723	0.670	1.098	0.691	1.637	1.207	1.995	0.617		1.971	1.387		1.028	1.747	1.725	1.406	0.982	2.068	3.284	0.507	5.893	2.622		1.226	1.226	1.495	1.759		0.816	
16(17)-EpDPE	1.347	1.803	0.972	1.495	0.950		1.432	1.104	0.492		1.887	0.655	1.192		0.613		2.662	2.418	1.855	2.339	1.490	1.099	6.442	1.522			3.618	0.533		0.335	1.051	1.334	1.543			1.673	0.877		0.549	1.097	1.039		0.475	1.012	2.089	0.616	3.601	1.786	0.726		0.915	0.661	0.913		0.434	
19(20)-EpDPE	2.311	2.445	2.138	2.750	2.247	2.825	2.257	1.609	1.409	0.566	3.514	1.607	2.158	1.109	0.668	2.044	6.828	7.157	2.136	3.747	2.089	2.178	7.794	2.515	1.380	0.851	10.898	1.432	2.830	1.210	1.458	1.855	2.052	1.373	1.044	2.730	2.392	1.093	1.204	1.049	2.850	1.660	1.235	1.563	3.177	1.116	5.235	3.668	1.286	1.527	2.741	1.294	1.959	1.264	1.353	1.142
9,10-DiHOME	26.560	55.848	24.809	66.938	33.230	24.020	18.656	25.422	18.403	7.159	48.441	9.620	17.806	9.720	12.936	20.314	178.717	386.029	43.033	38.537	19.087	28.326	66.202	62.767	23.243	22.983	459.667	25.710	26.789	54.733	10.226	23.746	29.836	37.128	15.870	43.850	47.872	26.385	12.481	61.272	33.094	28.628	81.933	33.863	63.187	39.638	50.225	45.962	17.375	51.265	20.509	52.728	23.725	17.730	10.009	13.182
12,13-DiHOME	23.458	30.570	28.761	82.293	30.724	20.368	20.180	20.493	10.912	6.178	59.164	6.827	16.963	7.791	11.379	13.268	105.636	221.534	21.513	23.172	16.533	40.691	44.388	54.468	18.544	16.218	306.089	19.034	27.778	33.920	8.032	15.399	20.166	25.809	12.804	30.768	37.079	20.694	9.430	42.402	37.485	30.461	53.678	23.938	44.458	29.074	39.288	31.715	11.670	42.239	12.742	49.910	18.451	14.300	7.681	10.111
5,6-DiHETrE	0.570	0.868	1.750	1.649	1.676	3.879	4.671	1.278	1.149	1.464	5.881	1.576	1.648	1.507		0.636	2.050	1.287		1.064	0.453	0.814		1.037	0.517	0.679	0.791		1.371	0.353		0.747	1.138	0.497	1.436	0.354	0.848	0.695	0.421	0.435	1.392	1.218		0.637	0.425	0.314				0.598	0.492	0.916	0.642	0.960		
8,9-DiHETrE	1.040	0.558	4.578	6.220	3.373	3.330	2.517	0.965		0.567	9.816	1.001	2.229	0.959	0.660	0.865	0.925			0.954	0.505	1.541		1.447	0.531	0.472		0.367	2.750	0.414	0.590	0.679	0.889	1.114	0.624		0.997			0.642	1.590	1.389	0.297	0.586	0.551	0.605		0.511	0.229	0.668	0.597	0.995	0.545	0.468	0.109	0.310
11,12-DiHETrE	11.861	6.394	42.194	73.827	37.547	34.770	20.166	7.486	6.156	5.201	77.039	10.092	21.166	9.750	5.075	6.211	11.429	4.289	1.242	13.254	6.029	14.447	7.434	13.091	4.980	3.580	4.071	2.688	20.241	5.702	5.000	6.096	7.575	12.513	7.441	3.192	7.455	4.151	2.062	2.488	13.709	13.810	1.361	3.948	5.177	4.710	1.158	4.315	2.159	4.580	3.363	9.760	4.964	3.524	1.360	1.773
14,15-DiHETrE	29.558	18.843	107.514	216.815	100.897	72.731	37.268	19.181	12.039	11.452	171.837	20.281	47.379	19.055	12.247	11.994	31.722	16.850	2.716	35.908	15.123	35.099	17.254	32.967	11.144	6.791	10.408	6.201	46.316	18.567	13.014	15.235	19.978	29.239	16.476	5.016	12.108	10.985	4.274	6.473	30.888	31.413	5.834	8.874	12.157	15.320	3.559	12.928	5.624	11.336	6.132	30.866	12.810	8.925	2.883	5.017
5,6-DiHETE(EPA)	0.835	1.253		1.339	2.973		1.149	1.127	0.400		3.893	1.036	1.152	1.163							0.508								1.413	0.628			1.750	1.044	0.816						0.436			0.245	0.705			0.252	0.444		0.761			0.682		
19,20-DiHDoPE	0.958	0.764	1.399	3.424	5.462	1.644	1.210	0.681	0.521		2.438	0.468	1.291		0.885	0.971	5.559	3.716	1.007	3.831	1.558	2.575	8.990	3.364	1.842	1.408	6.768	1.172	2.375	1.196	1.150	1.074	1.247	1.968	1.322	1.336	1.208	1.041	0.794	1.267	2.247	1.688	0.635	1.222	3.826	1.115	1.750	1.673	0.519	1.565	0.816	1.620	0.956	1.367	0.518	0.618
9-OxoODE	538.664	1106.091	518.346	754.071	519.622	683.362	661.788	662.349	216.555	238.971	1223.230	239.431	429.130	424.128	240.205	566.260	5892.786	6210.859	1500.746	1213.397	290.667	618.705	1963.111	529.591	413.382	396.590	9639.595	540.449	639.636	491.161	248.367	582.933	803.875	375.315	514.469	577.121	519.456	610.325	276.041	784.473	413.284	585.771	326.554	475.139	971.129	329.216	1426.311	858.604	264.218	619.137	316.607	544.627	430.777	421.308	179.092	289.721
13-OxoODE	577.406	1593.451	517.701	968.562	997.954	1193.836	822.766	855.999	404.792	267.313	1424.435	273.751	400.346	468.438	276.591	743.797	7331.277	11450.749	1489.624	1366.282	599.126	714.114	4531.223	1058.211	872.575	438.446	17358.556	659.748	682.956	848.115	267.758	608.319	905.202	583.530	576.330	569.439	482.814	703.536	273.180	1200.070	652.542	670.625	393.742	603.411	1459.948	409.105	1633.619	839.999	274.292	778.048	461.063	541.538	443.948	374.353	184.104	306.844
9-OxoOTrE	11.965	51.304	8.738	22.112	4.292	13.245	9.343	18.220	7.779	6.054	19.674	8.149	6.727	8.227	6.498	21.090	369.904	599.431	58.649	31.646	14.415	12.144	124.733	17.835	10.059	13.621	892.839	19.240	11.158	27.154	5.802	17.123	13.754	13.370	11.440	22.522	13.634	20.209	9.518	33.388	13.170	12.730	12.396	9.920	27.151	11.090	46.782	15.410	7.850	21.999	9.306	10.635	7.623	11.800	5.020	9.303
15-OxoEDE				5.136	3.738	3.212	2.113	2.805			8.986		2.532				16.546	16.600	3.548	3.665	1.163		19.878				21.912	1.080	3.757	2.515				2.811											2.359							3.013	0.798	1.832		
5-oxoETE																																																								
12-OxoETE																																																								
15-OxoETE	21.825	25.045	27.516	59.086	69.047	67.661	55.070	25.170	16.886	13.693	78.281	25.809	34.659	23.271	9.629	15.298	13.406			37.529	13.478	15.628	38.515	14.461	10.896			12.942	23.961	8.858	9.368	12.729	26.389	16.167	17.167	7.827	10.200	9.558	11.457	11.951	19.579	12.122	9.464	12.722	19.960		21.331	18.875	9.189	14.686	23.365	14.200	16.622	14.564	6.966	13.829
LXA4	1.044			5.248	4.918	2.224	1.448		0.880	0.390	7.462	0.707	2.285		1.058				0.264				2.692						1.032	0.388		0.555	2.277								0.698	0.323				0.415						0.736	0.345			0.179
15-epi LXA4		0.301	0.335	0.685	0.746		0.542		0.280	0.255	0.582	0.182	0.622		0.297	0.366													0.450	0.220					0.282											0.386	0.130		0.349	0.336	0.314	0.453				
15-oxo LXA4	0.591	1.163	1.674	1.668	1.577		1.570				0.992				0.903	0.750					0.605				0.623			0.473							0.342											1.004			0.496	0.465	0.685					
LXA5								0.175										1.810	0.216		1.267	0.889	6.721	2.805		1.623	5.974	0.959				0.420	1.542	1.235		1.052	0.862		0.247		1.618		0.361	2.271	0.727							1.103	1.270	3.690	1.713	0.948
LXB4										0.415																			2.876		0.865			5.021				0.924			2.096	1.177										6.269				0.462
RvD1												1.612	3.113		6.441				3.505	2.956					1.835							3.146										4.324		2.277		1.304							1.584		1.895	
RvD2				3.762																4.864		6.371	12.233	5.594	4.755	5.134	12.295	2.441	1.044		3.363	3.266		2.110								4.128		6.514	3.776			18.534	1.875	1.914	3.410	2.233	4.827	3.041	2.093	
RvD3																																																								
AT-RvD3	1.171								1.490		1.678	1.057				1.355																				0.740													0.521			0.690			0.485	
RvD4			0.533																																																0.550					
RvD5																																																								
RvD6 (4,17-DiHDoHE)	0.890	1.130		1.042		1.042		0.890			1.624	0.451	0.807	0.521		0.702			0.493	1.151	0.643		2.723	0.907	0.651								1.027	0.796					0.344		0.501			0.589	0.584		0.619	0.892		0.558		0.381	0.561	0.501		
8-oxoRvD1																																																								
17-oxoRvD1																																																								
RvD5(n-3DPA) (7,17-DiHDoPE)																																																								
RvE1																																				0.500																				
RvE2			0.094												0.202					0.547		2.294	3.005	2.619	0.623	0.492	3.035	1.976	0.871	0.765	0.162	0.225	0.240	1.121	0.546	0.492	1.473	0.831	0.532	0.910	1.689	0.553		0.255	0.538	0.950	0.614		0.228	0.278	0.159	1.698	0.553			
RvE3				3.431	3.750														1.856	2.058		2.230	10.184	1.804																			0.702													
PD1																																																						0.549		
AT-PD1																																																								
PD1(n-3, DPA)	101.454	99.788	67.036		67.966	106.769	90.900	80.206	66.065	98.334	53.459	72.588	133.312	105.419	66.031	78.006	189.074	120.525	165.265		55.458	94.022		33.777	63.932	83.362																														
10S,17S-DiHDoHE						8.433	3.917																				9.333																									2.590				
22-OH-PD1																																																								
Maresin1								0.719							0.519																													0.538												
7(S)-Maresin1															0.536																						0.720				1.090															
MaR1(n-3DPA)				1.519	1.221	2.543						0.517																																								2.298				
MS_METABOLITE_DATA_END
#METABOLITES
METABOLITES_START
metabolite_name	KEGG ID	PubChem ID	quantified m/z
13,14dhPGE1		161273	356
13,14dh-15k-PGE1		16061097	372
D17-PGE1		5283114	352
PGE1	C04741	7312	354
15(R)-PGE1		5283056	354
15-keto PGE1	C04654	5280710	352
Bicyclo PGE1		5283055	338
19(R)-hydroxy PGE1		5283115	370
2,3-dinor PGE1		16061101	326
PGE2	C00584	5280360	352
15-keto PGE2	C04707	5280719	350
13,14dh-15k-PGE2	C04671	5280711	352
Bicyclo PGE2		137699601	334
PGA2	C05953	5280880	334
tetranor PGEM		161468	328
PGE3	C06439	5280937	350
PGD2	C00696	448457	352
PGJ2	C05957	5280884	334
D12-PGJ2	C05958	5280885	334
15d-D12,14-PGJ2	C14717	5311211	316
13,14dh-15k-PGD2		5283036	352
PGD3	C13802	5282260	350
15d-D12,14-PGJ3
PGF1a	C06475	5280939	356
PGF2a	C00639	5280363	354
15-keto PGF2a	C05960	5280887	352
13,14dh-15k-PGF2a		5283039	354
PGF3a	C06476	5280940	352
iPF-VI		42607309	354
6kPGF1a	C05961	5280888	370
6-keto PGE1	C05962	5280889	368
6,15-diketo PGFa		174013	370
TXB2	C05963	5283137	370
11dh-TXB2	C05964	5280891	368
2,3-dinor TXB2		5283138	342
11dh-2,3-dinor TXB2		35024530	340
TXB3		5283140	368
11dh TXB3		16061115	366
LTB4	C02165	5280492	336
12-OxoLTB4		5283130	334
20-hydroxy LTB4	C04853	5280745	352
20-COOH LTB4	C05950	5280877	366
18-carboxy dinor LTB4		6438938	338
LTB5		5283125	334
5(S),6(S)-DiHETE		5283161	336
5(S),12(S)-DiHETE		9997164	336
5(S),15(S)-DiHETE		5283158	336
8(S),15(S)-DiHETE		5283183	336
5(S),15(S)-DiHEPE		5283180	368
9-HODE		5283944	296
13-HODE	C14762	6443013	296
9(S)-HOTrE	C16326	6439873	294
13(S)-HOTrE	C16316	16061072	294
13(S)-HOTrE(g)		5282971	294
11(R)-HEDE		16061090	324
15(S)-HEDE		5282705	324
8(S)-HETrE		5283148	322
5(S)-HETrE		5283143	322
5-HETE	C04805	5280733	320
8-HETE	C14776	5283154	320
9-HETE		14123398	320
11-HETE		5312982	320
12-HETE	C14777	5283155	320
15-HETE		9966861	320
20-HETE	C14748	5283157	320
tetranor 12-HETE		5282970	266
12(S)-HHTrE		5283141	280
5-HEPE		6439678	318
8-HEPE		16061128	318
9-HEPE		16061129	318
11-HEPE		16061130	318
12-HEPE		10041593	318
15(S)-HEPE		16061131	318
18-HEPE		16061132	318
4-HDoHE		14429109	344
7-HDoHE		16061142	344
8-HDoHE		11976798	344
10-HDoHE		11537494	344
11-HDoHE		11631564	344
13-HDoHE		11559259	344
14-HDoHE		11566378	344
16-HDoHE		11595378	344
17-HDoHE		6439179	344
20-HDoHE		16061143	344
9(10)-EpOME	C14825	6246154	296
12(13)-EpOME	C14826	5356421	296
5(6)-EpETrE	C14768	5283202	320
8(9)-EpETrE	C14769	5283203	320
11(12)-EpETrE	C14770	5283204	320
14(15)-EpETrE	C14771	5283205	320
8(9)-EpETE		16061085	318
11(12)-EpETE		16061087	318
14(15)-EpETE		16061088	318
17(18)-EpETE	C13843	16061089	318
7(8)-EpDPE		11653103	344
10(11)-EpDPE		11638767	344
13(14)-EpDPE		11674605	344
16(17)-EpDPE		14392758	344
19(20)-EpDPE		11631565	344
9,10-DiHOME		5282958	314
12,13-DiHOME		5282961	314
5,6-DiHETrE	C14772	5283142	338
8,9-DiHETrE	C14773	5283144	338
11,12-DiHETrE	C14774	5283146	338
14,15-DiHETrE	C14775	5283147	338
5,6-DiHETE(EPA)		14429105	336
19,20-DiHDoPE		16061148	362
9-OxoODE		5283011	294
13-OxoODE	C14765	6446027	294
9-OxoOTrE		11380794	292
15-OxoEDE		5283013	322
5-oxoETE	C14732	5283159	318
12-OxoETE	C14807	5283162	318
15-OxoETE	C04577	5280701	318
LXA4	C06314	5280914	352
15-epi LXA4		9841438	352
15-oxo LXA4		5221886	350
LXA5		6439927	350
LXB4	C06315	5280915	352
RvD1		16126783	376
RvD2		53477504	376
RvD3		53477497	376
AT-RvD3		44251573	376
RvD4		53477505	376
RvD5		25073195	360
RvD6 (4,17-DiHDoHE)		25073193	360
8-oxoRvD1		53477507	374
17-oxoRvD1		44576257	374
RvD5(n-3DPA) (7,17-DiHDoPE)
RvE1	C18171	10473088	350
RvE2	C18173	16061125	334
RvE3		56848721	334
PD1		16042541	360
AT-PD1		24778497	360
PD1(n-3, DPA)		86288884	362
10S,17S-DiHDoHE		11667655	360
22-OH-PD1
Maresin1		60201795	360
7(S)-Maresin1		42607314	360
MaR1(n-3DPA)		132472313	362
METABOLITES_END
#END